Clinical trials: Anemia, Aplastic
Fanconi Anemia, Severe Marrow Failure
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA).
- Conditions
- Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
- Trial name
- RAFA (NCT02143830)
- Testing
- Busulfan, Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Aplastic Anemia
Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia
Aplastic anemia (AA) is a rare bone marrow failure disease characterized by bone marrow hypocellularity and peripheral blood pancytopenia.
- Trial name
- NCT05399732
- Testing
- Luspatercept, Cyclosporine
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Bing Han
Severe Aplastic Anemia
Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia
The purpose of this study was to evaluate the efficacy and safety of eltrombopag in combination with cyclosporine alone as first-line therapy on overall hematologic response
- Trial name
- SOAR (NCT02998645)
- Testing
- eltrombopag, Cyclosporine
- Where
- 20 sites in Brazil, Hong Kong and 7 more
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Transfusion-dependent Non-severe Aplastic Anemia
Enarodustat+CsA vs CsA in the Treatment of Newly-diagnosed TD-NSAA
This study aimed to compare the efficacy and safety of enarodustat combined with cyclosporine versus cyclosporine alone in the treatment of TD-NSAA.
- Trial name
- NCT07522996
- Testing
- Enarodustat, Cyclosporin (CSA)
- Sponsor
- Peking Union Medical College Hospital
Severe Aplastic Anemia
Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
This study is a prospective, multicenter phase II study with patients receiving haploidentical transplantation for Severe Aplastic Anemia (SAA).
- Trial name
- CHAMP (NCT02918292)
- Testing
- Antithymocyte Globulin (ATG), Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States
- Volunteers
- 32 people
- Sponsor
- Medical College of Wisconsin
Leukemia, Lymphoma
New York Blood Center National Cord Blood Program
Umbilical cord blood is used as a source of hematopoietic stem cells for bone marrow reconstitution in patients who would be potential candidates for a bone marrow transplant from an unrelated marrow donor.
- Conditions
- Leukemia, Lymphoma, Genetic Disease, Severe Aplastic Anemia
- Trial name
- NCT00212407
- Testing
- Umbilical Cord Blood Transplantation
- Where
- United States
- Volunteers
- 4,476 people
- Sponsor
- New York Blood Center
Hematologic Malignancy, Myelodysplastic Syndrome (MDS)
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Subjects will be diagnosed with a hematological malignancy (cancer of the blood), which is unlikely to be cured with conventional non-transplant therapy.
- Conditions
- Hematologic Malignancy, Myelodysplastic Syndrome (MDS), Aplastic Anemia
- Trial name
- NCT00673114
- Testing
- haplo/cord transplant
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Joanne Kurtzberg, MD
AML, ALL
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
The purpose of this study is to provide allogeneic stem cell transplantation to patients who have not traditionally undergone this procedure because of it high incidence of treatment related side effects.
- Conditions
- AML, ALL, CML Chronic Phase, Accelerated Phase, or Blast Crisis, CLL
- Trial name
- MINI HEME (NCT00636909)
- Testing
- Cyclophosphamide, fludarabine, cyclosporine
- Volunteers
- 25 people
- Sponsor
- Beth Israel Deaconess Medical Center
Fanconi Anemia, Autosomal or Sex Linked Recessive Genetic Disease
Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents
Fanconi anemia is a rare autosomal or sex linked recessive genetic disease. The disease is characterized by bone marrow hematopoiesis failure, multiple congenital abnormalities, and susceptibility to neoplastic diseases.
- Conditions
- Fanconi Anemia, Autosomal or Sex Linked Recessive Genetic Disease, Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases., Hematopoiesis Maintainance.
- Trial name
- NCT01995305
- Testing
- human whole exome, whole genomic
- Where
- China
- Sponsor
- Xiaofan Zhu
Leukemia, Lymphoma
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
The main purpose of this study is to assess the effects of cyclophosphamide (cytoxan) in the post transplant setting to prevent onset of acute graft-versus-host disease (GVHD).
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- NCT02065154
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Alabama at Birmingham
Fanconi Anemia, Unspecified Adult Solid Tumor, Protocol Specific
Tissue Sample Collection From Patients With Fanconi Anemia
RATIONALE: Collecting and storing samples of tumor tissue from patients with Fanconi anemia to test in the laboratory may help the study of cancer in the future.
- Conditions
- Fanconi Anemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00899522
- Testing
- biologic sample preservation procedure, biopsy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- OHSU Knight Cancer Institute
Severe Aplastic Anemia
Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly
This is a multicenter, single-arm clinical study. The objective was to evaluate the efficacy and safety of CSA in combination with Avatrombopag in elderly patients with very/sever aplastic anemia treated for the first time.
- Trial name
- SAA (NCT05433922)
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Aplastic Anemia
CK0801 for Treatment of Aplastic Anemia
This Phase 2, multicenter, open-label study is evaluating CK0801 for the treatment of aplastic anemia in adults with persistent transfusion dependence after at least one prior line of therapy or intolerance to standard-of-care…
- Trial name
- NCT07499102
- Testing
- CK0801
- Volunteers
- 12 people
- Sponsor
- Cellenkos, Inc.
Anemia, Aplastic, Hematologic Diseases
Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders
To determine the therapeutic effects of anti-thymocyte globulin (ATG) in patients with aplastic anemia and related bone marrow failure diseases.
- Conditions
- Anemia, Aplastic, Hematologic Diseases, Pancytopenia, Blood Disease
- Trial name
- NCT00000597
- Testing
- antilymphocyte serum, nandrolone
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Fanconi Anemia
Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia
Background: Fanconi anemia (FA) is a rare, inherited cancer syndrome. FA causes a range of physical issues. Children with FA may have abnormal features; these may include a small head and eyes and issues with their internal…
- Trial name
- NCT06744283
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Severe Aplastic Anemia, Refractory Aplastic Anemia
Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia
This study is designed as a Phase Ib/II trial. The phase Ib cohort will enroll patients with severe aplastic anemia (SAA) who have failed to respond to intensified immunosuppressive therapy.
- Conditions
- Severe Aplastic Anemia, Refractory Aplastic Anemia, Newly Diagnosed Aplastic Anemia
- Trial name
- NCT07297550
- Testing
- Golidocitinib Capsules
- Volunteers
- 42 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematologic Neoplasms, Anemia, Aplastic
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
The purpose of this study is to transplant haploidentical related peripheral blood stem cells (PBSCs) that come from a relative such as a parent, sibling, a child or other relative who has a half-matched tissue type with the…
- Conditions
- Hematologic Neoplasms, Anemia, Aplastic, Hemoglobinuria, Paroxysmal, Multiple Myeloma
- Trial name
- NCT00618969
- Testing
- haploidentical allogeneic PBSC transp
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Arizona
Aplastic Anemia
Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia
Rationale: Chemotherapy with fludarabine, cyclophosphamide and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic hematopoietic cell transplantation.
- Trial name
- NCT01105273
- Testing
- anti-thymocyte globulin, filgrastim, Fludarabine
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Asan Medical Center
Severe Aplastic Anemia, Hematopoietic Cell Transplant
Thiotepa-Based Conditioning for Haploidentical Hematopoietic Stem Cell Transplantation in Older Patients With Severe Aplastic Anemia
This prospective, single-center observational cohort study will follow participants aged 50 years or older with severe or very severe aplastic anemia who receive haploidentical hematopoietic stem cell transplantation with a…
- Trial name
- NCT07819812
- Testing
- Thiotepa
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization.
- Conditions
- Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis
- Trial name
- NCT04439006
- Testing
- Best Practice, Ibrutinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jennifer Woyach